Placental malaria is rare among zanzibari pregnant women who did not receive intermittent preventive treatment in pregnancy

listen audio

Study Justification:
The study aimed to investigate the prevalence of placental malaria among pregnant women in Zanzibar who did not receive intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine. This was important because Zanzibar has transitioned to the pre-elimination phase of malaria control, and there were questions about the continued need for IPTp. Understanding the prevalence of placental malaria in this population would help inform the Ministry of Health’s decision on whether to discontinue IPTp.
Study Highlights:
– The study was conducted from August 2011 to September 2012 in six health facilities in Zanzibar.
– A convenience sample of pregnant women who did not receive IPTp was enrolled on the day of delivery.
– Placental blood spot specimens were analyzed using polymerase chain reaction (PCR) to detect Plasmodium falciparum infection.
– Out of 1,349 specimens analyzed, only 9 (0.7%) were PCR-positive for Plasmodium falciparum.
– Placental malaria infection was detected on both the islands of Pemba and Unguja.
– The low prevalence of placental malaria suggests that IPTp may not be necessary in Zanzibar.
Recommendations for Lay Reader and Policy Maker:
Based on the study findings, the following recommendations can be made:
1. The Ministry of Health should consider discontinuing IPTp for pregnant women in Zanzibar.
2. Surveillance efforts for malaria should be intensified to monitor the prevalence of placental malaria and overall malaria transmission.
3. Promotion of insecticide-treated nets and effective case management of malaria in pregnancy should be prioritized.
Key Role Players:
To address these recommendations, the following key role players may be needed:
1. Ministry of Health officials
2. Public health experts
3. Health facility staff
4. Community health workers
5. Researchers and scientists
Cost Items for Planning Recommendations:
While the actual cost may vary, the following budget items should be considered in planning the recommendations:
1. Training and capacity building for health workers on malaria surveillance and case management.
2. Procurement and distribution of insecticide-treated nets.
3. Monitoring and evaluation of malaria control programs.
4. Research and data collection on malaria prevalence and transmission.
5. Health education and awareness campaigns for pregnant women and the general population.
Please note that the above cost items are estimates and may need to be adjusted based on the specific context and resources available in Zanzibar.

The strength of evidence for this abstract is 7 out of 10.
The evidence in the abstract is moderately strong. The study conducted a prospective observational study to estimate placental malaria positivity rate among women who did not receive IPTp with sulfadoxine-pyrimethamine. The study used a convenience sample of pregnant women from six clinics in Zanzibar. Placental blood spot specimens were analyzed using polymerase chain reaction (PCR) and 9 out of 1,349 specimens (0.7%) were PCR-positive for Plasmodium falciparum. The study provides specific numbers and percentages, which adds to the strength of the evidence. However, the study used a convenience sample, which may introduce bias. To improve the strength of the evidence, a larger sample size and a more representative sampling method could be used.

Zanzibar has transitioned from malaria control to the pre-elimination phase, and the continued need for intermittent preventive treatment during pregnancy (IPTp) has been questioned. We conducted a prospective observational study to estimate placental malaria positivity rate among women who did not receive IPTp with sulfadoxinepyrimethamine. A convenience sample of pregnant women was enrolled from six clinics on the day of delivery from August of 2011 to September of 2012. Dried placental blood spot specimens were analyzed by polymerase chain reaction (PCR); 9 of 1, 349 specimens (0. 7%; precision estimate = 0. 2-1. 1%) were PCR-positive for Plasmodium falciparum. Placental infection was detected on both Pemba (N = 3) and Unguja (N = 6). Placental malaria positivity in Zanzibar was low, even in the absence of IPTp. It may be reasonable for the Ministry of Health to consider discontinuing IPTp, intensifying surveillance efforts, and promoting insecticide-treated nets and effective case management of malaria in pregnancy. Copyright © 2014 by The American Society of Tropical Medicine and Hygiene.

Zanzibar is comprised of two main islands approximately 40 km from mainland Tanzania: Unguja (2012 population = 896,721; 1,666 km2) and Pemba (2012 population = 406,848; 998 km2).15,16 This study was conducted at a purposive sample of 6 of 38 health facilities in Zanzibar where routine deliveries occur (3 facilities in Unguja [Mnazi Mmoja Hospital, Mwembeladu Hospital, and Kivunge Health Center] and 3 facilities in Pemba [Chake Chake Hospital, Wete Hospital, and Micheweni Health Center]) from August of 2011 to September of 2012. These facilities were engaged in an ongoing program supported by the US Agency for International Development (USAID) designed to improve maternal and newborn health services. Although these six hospitals covered approximately 82% of hospital deliveries on both islands, 50% of women in Zanzibar deliver at home.17 The peak rainfall period occurs from March to June, and the peak malaria transmission period is from April to July.18 Residents of Unguja or Pemba delivering at a study facility were considered eligible if their antenatal care (ANC) card indicated they had received no doses of IPTp SP. Women were enrolled 24 hours/day every day of the week by the clinic staff. Consecutive sampling was used to enroll all eligible women during the 12-month study period. However, because of the added burden on the clinic staff, no listing was maintained of women who were eligible but not enrolled. The 12-month enrollment ensured that both low- and high-transmission seasons were represented. Women who delivered at the six facilities were screened by examining their ANC card, which contains a designated space for recording doses of IPTp SP received. No additional questions were asked, because eligible clients were typically in active labor. Eligible women who agreed to participate were read an informed consent statement by trained maternity nurses or nurse midwives, and their verbal consent was obtained and recorded. No additional assent options were offered to minors. A brief form, including age of mother, gravidity, hemoglobin or hematocrit and week of gestation at which the measurement was taken, whether it was a singleton or multiple birth, outcome of the birth, and birth weight of the baby, was filled out by the health worker with information extracted from each consenting mother’s ANC card. The form was placed into the client’s file and transferred to the delivery room with the client. After management of the birth, a trained maternity nurse or nurse midwife at each facility obtained a placental dried blood spot (DBS) specimen from the maternal side of the placenta. A single deep incision was made, and five drops of blood were drawn up with a pipette and dotted onto Whatman 903 Protein Saver Card filter paper labeled only with the woman’s study identification (ID) number.19,20 DBS specimens were labeled, packed with desiccant, and transferred to the University of California, San Francisco for polymerase chain reaction (PCR) to detect infection with Plasmodium (all species). Although exact timing was not monitored, collection of each specimen generally occurred within 30 minutes of delivery. After collection of the specimen, the placenta was disposed of per the facility’s routine procedures. Multiple births were noted on the client’s study form. In the case of twins with one placenta, one ID was issued. In the case of twins with two placentas, each placenta was assigned a unique ID number and tested. Corresponding placental ID numbers were noted on the client form. DNA from each DBS was extracted using the QIAamp DNA Microkit following the manufacturer’s instructions (Qiagen, Germantown, MD). Plasmodium DNA was amplified by 18S ribosomal DNA PCR, with the species-specific nested round confirming falciparum species.21 The presence of PCR product was evaluated using agarose gel electrophoresis stained with ethidium bromide. Testing of control samples extracted from DBSs with known parasite densities confirmed a limit of detection of < 10 parasite/μL. The required sample size was calculated to be 1,825 assuming a parasitemia prevalence of 5% with a 95% confidence interval with precision of ±1% point. The sample size was calculated assuming independence of observations, because intracluster correlations could not be assessed, but the expected prevalence was liberally estimated to help account for unknown variables. Initial results indicated prevalence well under the liberal prevalence estimate used in the sample size assumptions, indicating that fewer samples were needed to attain the necessary power for the study, but data collection continued to allow for coverage throughout both the rainy and dry seasons. Client forms were entered into an Access database and date stamped, and hard copies were filed chronologically along with the consent forms. Data on PCR status were provided in an Excel spreadsheet, and the ID numbers were matched between the two files. Cleaned data were exported into SPSS, version 20 and Stata, version 11 for analysis. Although we attempted to enroll all eligible women, given the total number of deliveries and the expected proportion of women who did not receive IPTp (25%),14 it is likely that some of the eligible women were not enrolled. Given that the participants in this study were a non-probability sample of all eligible women, the 95% confidence interval given for the proportion of women with placental parasitemia who did not receive IPTp is considered a precision interval rather than a confidence interval. Ethical approval was provided by the Zanzibar Research Council, Johns Hopkins School of Public Health Institutional Review Board, and the US Centers for Disease Control and Prevention, Atlanta.

Based on the provided information, here are some potential innovations that could be used to improve access to maternal health:

1. Mobile Health (mHealth) Solutions: Develop mobile applications or SMS-based systems to provide pregnant women with information and reminders about antenatal care, IPTp, and other important aspects of maternal health.

2. Telemedicine: Implement telemedicine services to enable pregnant women in remote or underserved areas to consult with healthcare professionals and receive prenatal care remotely.

3. Community Health Workers: Train and deploy community health workers to provide education, counseling, and basic antenatal care services to pregnant women in their communities, particularly those who deliver at home.

4. Incentives for Facility-Based Deliveries: Introduce incentives, such as cash transfers or vouchers, to encourage pregnant women to deliver at health facilities where they can receive comprehensive maternal health services.

5. Strengthening Surveillance Systems: Improve surveillance systems to monitor and track maternal health indicators, including placental malaria, to inform decision-making and resource allocation for maternal health programs.

6. Integration of Services: Integrate maternal health services with other existing healthcare programs, such as malaria control programs, to ensure comprehensive care for pregnant women.

7. Quality Improvement Initiatives: Implement quality improvement initiatives in healthcare facilities to enhance the quality of maternal health services, including antenatal care, delivery, and postnatal care.

8. Public-Private Partnerships: Foster partnerships between the public and private sectors to leverage resources, expertise, and innovation for improving access to maternal health services.

9. Maternal Health Financing: Explore innovative financing mechanisms, such as health insurance schemes or microfinance initiatives, to ensure financial protection and affordability of maternal health services for all women.

10. Behavior Change Communication: Develop targeted behavior change communication campaigns to raise awareness and promote positive health-seeking behaviors among pregnant women, their families, and communities.

It is important to note that the implementation of these innovations should be context-specific and tailored to the local healthcare system and needs of the population.
AI Innovations Description
Based on the provided description, the recommendation to improve access to maternal health is to consider discontinuing intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine in Zanzibar. This recommendation is based on the findings of a study that showed a low prevalence of placental malaria among pregnant women who did not receive IPTp. Instead, the Ministry of Health could focus on intensifying surveillance efforts, promoting the use of insecticide-treated nets, and ensuring effective case management of malaria in pregnancy. This approach may help improve access to maternal health by redirecting resources towards other interventions that have proven to be effective in reducing the risk of malaria during pregnancy.
AI Innovations Methodology
Based on the provided description, here are some potential recommendations to improve access to maternal health:

1. Increase access to antenatal care (ANC): Promote and provide easy access to ANC services for pregnant women, ensuring that they receive regular check-ups, screenings, and necessary interventions.

2. Strengthen health facilities: Improve the infrastructure, equipment, and staffing of health facilities to ensure they can provide quality maternal health services, including skilled birth attendance, emergency obstetric care, and postnatal care.

3. Enhance community-based interventions: Implement community-based programs that educate and empower women and their families about maternal health, including the importance of ANC, skilled birth attendance, and postnatal care. This can be done through community health workers, mobile clinics, and community outreach programs.

4. Improve transportation services: Address transportation barriers by providing reliable and affordable transportation options for pregnant women to access health facilities for ANC, delivery, and postnatal care.

5. Strengthen referral systems: Establish effective referral systems between health facilities at different levels of care to ensure timely and appropriate management of complications during pregnancy and childbirth.

To simulate the impact of these recommendations on improving access to maternal health, a methodology could include the following steps:

1. Define indicators: Identify key indicators to measure the impact of the recommendations, such as the number of pregnant women receiving ANC, the percentage of deliveries attended by skilled birth attendants, and the availability of postnatal care services.

2. Collect baseline data: Gather data on the current status of maternal health access in the target population, including the number of pregnant women accessing ANC, the percentage of deliveries attended by skilled birth attendants, and the availability of postnatal care services.

3. Implement interventions: Introduce the recommended interventions in the target population, such as increasing access to ANC, strengthening health facilities, implementing community-based interventions, improving transportation services, and strengthening referral systems.

4. Monitor and evaluate: Continuously monitor the implementation of the interventions and collect data on the indicators defined in step 1. This can be done through surveys, interviews, and routine data collection systems.

5. Analyze data: Analyze the collected data to assess the impact of the interventions on improving access to maternal health. Compare the baseline data with the post-intervention data to determine any changes or improvements.

6. Interpret results: Interpret the findings to understand the effectiveness of the interventions in improving access to maternal health. Identify any gaps or areas that require further attention or modification.

7. Adjust interventions: Based on the results and interpretation, make necessary adjustments to the interventions to further improve access to maternal health.

8. Repeat the process: Continuously repeat the monitoring, evaluation, and adjustment process to ensure ongoing improvement in access to maternal health.

By following this methodology, policymakers and healthcare providers can assess the impact of different interventions and make informed decisions to improve access to maternal health.

Partagez ceci :
Facebook
Twitter
LinkedIn
WhatsApp
Email